QuidelOrtho Corp (QDEL): Operating Income

Annual figures by period end, from SEC filings.

-$919.20M

Year ended 2025-12-28

-$824.70M

Trailing 12 months to 2026-06-28

2021-01-03 Operating Income (USD) 2025-12-28

Period ended	Operating Income	Change YoY	Source filing
2025-12-28	-$919.20M	n/m	2026-02-19, From 2024-12-30
2024-12-29	-$1.96B	n/m	2026-02-19, From 2024-01-01
2023-12-31	$139.10M	-83.5%	2026-02-19, From 2023-01-02
2023-01-01, Fiscal 2022	$843.70M	-6.9%	2025-02-27, From 2022-01-03
2022-01-02, Fiscal 2021	$906.00M	-14.6%	2024-08-01, From 2021-01-04
2021-01-03, Fiscal 2020	$1.06B	n/a	2023-02-23, From 2019-12-30

Operating Income at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
QuidelOrtho Corp (QDEL)	2025-12-28	-$919.20M	n/m
Idexx Laboratories Inc (IDXX)	2025-12-31	$1.36B	+20.5%
Lantheus Holdings, Inc. (LNTH)	2025-12-31	$310.83M	-32.0%
Neogen Corp (NEOG)	2026-05-31	-$21.60M	n/m
Myriad Genetics Inc (MYGN)	2025-12-31	-$387.20M	n/m
Intellia Therapeutics, Inc. (NTLA)	2025-12-31	-$440.99M	n/m
Alpha Teknova, Inc. (TKNO)	2025-12-31	-$16.98M	n/m
Immucell Corp (ICCC)	2025-12-31	$1.65M	n/m
Aspira Women's Health Inc. (AWHL)	2025-12-31	-$7.91M	n/m

Compare QDEL, IDXX, LNTH, NEOG side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗